Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE)

July 4, 2025 updated by: Ra Pharmaceuticals, Inc.

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
174

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • London, Ontario, Canada, N6A 5A5
        • Site 44: London Health Sciences Centre University Hospital
    • Quebec
      • Montréal, Quebec, Canada, H3A 2B4
        • Site 11: Montreal Neurological Institute and Hospital (McGill University)
  • France
      • Angers Cedex 9, France
        • Site 191: Centre Hosptitalier Universitaire d'Angers
      • Lille, France
        • Site 204: Centre Hospitalier Régional Universitaire de Lille
      • Nice, France, 06000
        • Site 118: Hôpital Pasteur
      • Paris, France, 75013
        • Site 105: Pitié-Salpêtrière University Hospital
      • Strasbourg, France, 67091
        • Site 137: Les Hôpitaux Universitaires de Strasbourg
  • Germany
      • Göttingen, Germany, 37075
        • Site 150: Universitätsmedizin Göttingen
      • Tübingen, Germany, 72076
        • Site 129: Universitätsklinikum Tübingen
  • Italy
      • Milan, Italy, 20133
        • Site 126: Fondazione IRCCS Istituto Neurologico Carlo Besta
      • Roma, Italy, 20123
        • Site 132: Università Cattolica del Sacro Cuore - Campus di Milano
  • Japan
      • Chiba, Japan, 260-8677
        • Site 151: Chiba University Hospital
      • Iwata, Japan, 025-0075
        • Site 136: General Hanamaki Hospital
      • Kita-gun, Japan
        • Site 179: Kagawa University Hospital - Collagen disease/Rheumatic int
      • Nagasaki, Japan, 852-8501
        • Site 146: Nagasaki University Hospital
      • Sapporo, Japan, 063-0005
        • Site 152: Hokkaido Medical Center
      • Sendai, Japan, 983-8520
        • Site 144: Sendai Medical Center
      • Tokyo, Japan, 153-8515
        • Site 153: Toho University Ohashi Medical Center
      • Tokyo, Japan, 160-0023
        • Site 163: Tokyo Medical University Hospital
      • Tokyo, Japan, 160-8582
        • Site 141: Keio University Hospital
      • Tokyo, Japan, 565-0871
        • Site 165: Osaka University Hospital
    • Chiba
      • Narita, Chiba, Japan, 286-8520
        • Site 169: International University of Health and Welfare Narita Hospital
  • Norway
      • Bergen, Norway, 5021
        • Site 140: Haukeland University Hospital / Health Bergen
      • Oslo, Norway, 0450
        • Site 143: Oslo Universitetssykehus
  • Poland
      • Kraków, Poland
        • Site 193: Krakowska Akademia Neurologii - Centrum Neurologii Kliniczne
      • Kraków, Poland
        • Site 211: Specjalistyczne Gabinety Sp. z o.o.
      • Lublin, Poland, 20-093
        • Site 210: Clinhouse Centrum Medyczne
    • Lubelskie
      • Lublin, Lubelskie, Poland, 20-093
        • Site 205: Prywatny Gabinet Lekarski Urszula Chyrchel-Paszkiewicz
    • Lubuskie
      • Nowa Sól, Lubuskie, Poland, 67-100
        • Site 194: Twoja Przychodnia - Centrum Medyczne Nowa Sól
    • Lódzkie
      • Łódź, Lódzkie, Poland, 90-644
        • Site 214: AmiCare Centrum Medyczne
    • Malopolskie
      • Kraków, Malopolskie, Poland, 31-202
        • Site 192: Krakowski Szpital Specjalistyczny im. Jana Pawła II
    • Mazowieckie
      • Warszawa, Mazowieckie, Poland, 01-868
        • Site 201: Centrum Medyczne Pratia - Warszawa
    • Slaskie
      • Katowice, Slaskie, Poland, 40-123
        • Site 195: Wielospecjalistyczna Poradnia Lekarska Synapsis
      • Katowice, Slaskie, Poland, 40-650
        • Site 213: Niepubliczny Zakład Opieki Zdrowotnej NOVO-MED
    • Wielkopolskie
      • Poznań, Wielkopolskie, Poland, 61-853
        • Site 209: Niepubliczny Zakład Opieki Zdrowotnej NEURO - KARD
  • Spain
      • Barcelona, Spain, 08035
        • Site 133: Hospital Universitari Vall d'Hebrón
      • Barcelona, Spain
        • Site 168: Hospital de la Santa Creu i Sant Pau
      • Bilbao, Spain, 48013
        • Site 138: Hospital Universitario de Basurto
  • United Kingdom
      • Oxford, United Kingdom, OX3 9DU
        • Site 119: Oxford University Hospitals NHS Foundation Trust
      • Sheffield, United Kingdom, S10 2JF
        • Site 130: Royal Hallamshire Hospital
  • United States
    • Alabama
      • Mobile, Alabama, United States, 36604
        • Site 41: Diagnostic and Medical Clinic
    • Arizona
      • Phoenix, Arizona, United States, 85028
        • Site 116: Neuromuscular Clinic and Research Center
    • California
      • Los Angeles, California, United States, 90033
        • Site 4: University of Southern California
      • Orange, California, United States, 92868
        • Site 31: University of California Irvine
      • Pasadena, California, United States, 91101
        • Site 220: Investigator Site
      • San Francisco, California, United States, 94115
        • Site 160: Forbes Norris MDA/ALS Research and Treatment Center
    • Connecticut
      • New Haven, Connecticut, United States, 06510
        • Site 24: Yale University
    • District of Columbia
      • Washington, District of Columbia, United States, 20037
        • Site 27: George Washington University
    • Florida
      • Miami, Florida, United States, 33175
        • Site 182: Gelasio Baras Neurology
      • Tampa, Florida, United States, 33612
        • Site 25: University of South Florida
    • Georgia
      • Augusta, Georgia, United States, 30912
        • Site 135: Augusta University Medical Center
    • Hawaii
      • Honolulu, Hawaii, United States, 96817
        • Site 176: Hawaii Pacific Neuroscience
    • Illinois
      • Glenview, Illinois, United States, 60026-1339
        • Site 188: North Shore Medical Group - Glenview
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Site 156: Indiana University Health Neuroscience Center
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • Site 32: Kansas University Medical Center Research Institute
    • Massachusetts
      • Foxboro, Massachusetts, United States, 02035
        • Site 221: Neurology Center of New England
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Site 33: Detroit medical Center - University Health Center
      • East Lansing, Michigan, United States, 48824
        • Site 49: Michigan State University
    • Minnesota
      • Minneapolis, Minnesota, United States, 55455
        • Site 127: University of Minnesota
    • Missouri
      • Columbia, Missouri, United States, 65212
        • Site 134: Neurology and Sleep Disorders Clinic
    • Nevada
      • Las Vegas, Nevada, United States, 89145
        • Site 117: Las Vegas Clinic
    • New York
      • Great Neck, New York, United States, 11021
        • Site 123: Northwell Health Neuroscience Institute
      • New York, New York, United States, 10021
        • Site 23: Hospital for Special Surgery
      • New York, New York, United States, 10029
        • Site 47: Mount Sinai Hospital
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • Site 22: University of North Carolina
      • Durham, North Carolina, United States, 27710
        • Site 15: Duke University
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Site 122: Cleveland Clinic
      • Columbus, Ohio, United States, 43210
        • Site 38: Ohio State University
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15212
        • Site 40: Allegheny Neurological Associates
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Site 128: Medical University of South Carolina
    • Tennessee
      • Cordova, Tennessee, United States, 38018
        • Site 185: Neurology Clinic Cordova
    • Texas
      • Austin, Texas, United States, 78756
        • Site 131: Austin Neuromuscular Center
      • Dallas, Texas, United States, 75390
        • Site 19: University of Texas Southwestern
    • Utah
      • Salt Lake City, Utah, United States, 84132
        • Site 39: University of Utah
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • Site 164: University of Virginia Health System
    • Washington
      • Seattle, Washington, United States, 98195
        • Site 154: University of Washington
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53215
        • Site 45: Center for Neurological Disorders

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 74 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of gMG [Myasthenia Gravis Foundation of America (MGFA) Class II-IV] at Screening
  • Positive serology for acetylcholine receptor (AChR) autoantibodies
  • MG-ADL Score of ≥ 6 at Screening and Baseline
  • QMG score ≥ 12 at Screening and Baseline
  • No change in corticosteroid dose for at least 30 days prior to Baseline or anticipated to occur during the 12-week Treatment Period
  • No change in immunosuppressive therapy, including dose, for at least 30 days prior to Baseline or anticipated to occur during the 12-week Treatment Period

Exclusion Criteria:

  • Thymectomy within 12 months prior to Baseline or scheduled to occur during the 12 week Treatment Period
  • History of meningococcal disease
  • Current or recent systemic infection within 2 weeks prior to Baseline or injection requiring intravenous (IV) antibiotics within 4 weeks prior to Baseline

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo
Drug: Placebo
Daily subcutaneous (SC) injection
Experimental: 0.3 mg/kg zilucoplan (RA101495)
Drug: zilucoplan (RA101495)
Daily subcutaneous (SC) injection

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score
Time Frame: From Baseline to End of Treatment (Week 12)
The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale scored 0 to 3 (0=None, 3=severe disease) point scale. The total score was the sum of all individual item scores and ranged from 0 to 24. Higher scores indicated more severe disability due to MG. A decrease from Baseline score indicated improvement.
From Baseline to End of Treatment (Week 12)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change From Baseline to Week 12 in the Quantitative Myasthenia Gravis (QMG) Total Score
Time Frame: From Baseline to End of Treatment (Week 12)
The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consisted of 13 items. Each item in the scale scored on a 0 to 3-point scale, ranging from 0 (no weakness) to 3 (severe weakness), summing up to the overall score range from 0 to 39. Higher scores indicated more severe impairment. A decrease from Baseline score indicated improvement.
From Baseline to End of Treatment (Week 12)
Change From Baseline to Week 12 in the Myasthenia Gravis Composite (MGC) Scale Total Score
Time Frame: From Baseline to End of Treatment (Week 12)
The total MGC score was sum of responses to 10 individual items : 1. Ptosis upward gaze (0 to 3), 2. Double vision on lateral gaze, left or right (0, to 4), 3. Eye closure (0 to 2), 4. Talking (0 to 6), 5. Chewing (0 to 6), 6. Swallowing [0 to 6], 7. Breathing (0 to 9), 8. Neck flexion or extension (0 to 4), 9. Shoulder abduction (0 to 5), 10. Hip flexion (0 to 5). The higher score for each item indicated severity. The total score ranged 0 to 50 with higher score indicative of severe disease activity). A decrease from Baseline score showed improvement.
From Baseline to End of Treatment (Week 12)
Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life Revised (MG-QoL15r) Scale Total Score
Time Frame: From Baseline to End of Treatment (Week 12)
The MG-QoL15r is a 15-item patient-reported outcome measure designed to assess quality of life in patients with MG. Each item in the scale scored on a 0 to 2-point scale (0=Not much at all, 1=Somewhat, 2=Very much). The total score was the sum of the 15 individual item scores, ranging from 0 to 30. Higher scores indicated more severe impact of the disease on aspects of the patient's life. A decrease from Baseline score indicated improvement.
From Baseline to End of Treatment (Week 12)
Time to First Receipt of Rescue Therapy Over the 12-week Treatment Period
Time Frame: From Baseline to End of Treatment (Week 12)
Time to first receipt of rescue therapy over the 12-week treatment period (in days) was defined as the date of first rescue therapy use minus date of first Investigational Medicinal Product (IMP) + 1.
From Baseline to End of Treatment (Week 12)
Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 12 Without Rescue Therapy
Time Frame: End of Treatment (Week 12)
Percentage of Participants achieving MSE was defined as achieving a MG-ADL value of a 0 (No MG symptoms) or 1 (Mild MG symptoms) at Week 12 and not having taken rescue therapy. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the missing at Random (MAR) assumption.
End of Treatment (Week 12)
Percentage of Participants Achieving a ≥ 3-point Reduction in MG-ADL Score at Week 12 Without Rescue Therapy
Time Frame: End of Treatment (Week 12)
Percentage of participants achieving a ≥ 3-point reduction in MG-ADL Score at Week 12 without rescue therapy were reported. The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale scored on a 0 to 3 (0=None, 3=severe disease) point scale. The total score was the sum of all individual item scores and ranged from 0 to 24. Higher scores indicated more severe disability due to MG. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the MAR assumption.
End of Treatment (Week 12)
Percentage of Participants Achieving a ≥5-point Reduction in QMG Score Without Rescue Therapy at Week 12
Time Frame: End of Treatment (Week 12)
Percentage of participants achieving a ≥5-point reduction in QMG Score without rescue therapy at Week 12 were reported. The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consisted of 13 items. Each item in the scale scored on a 0 to 3-point scale, ranging from 0 (no weakness) to 3 (severe weakness), summing up to the overall score range from 0 to 39. Higher scores indicated more severe impairment. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the MAR assumption.
End of Treatment (Week 12)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: From Baseline (Day 1) to Safety Follow-up visit (19 Weeks [12 weeks Treatment Period plus up to 7 weeks Follow-up])
A TEAE is defined as an AE starting on or after the time of first administration of IMP and up to and including 40 days after the final dose (or last contact depending on which occurs first). Adverse events starting before the date of the first administration of IMP were not considered TEAEs.
From Baseline (Day 1) to Safety Follow-up visit (19 Weeks [12 weeks Treatment Period plus up to 7 weeks Follow-up])

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ra Pharmaceuticals, Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: UCB Cares, 0018445992273 (UCB)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 17, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 30, 2021

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 2, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 2, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 4, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 16, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 4, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RA101495-02.301

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed;in this case and to protect participants, individual patient-level data would not be made available.

IPD Sharing Time Frame

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

IPD Sharing Access Criteria

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myasthenia Gravis, Generalized

Clinical Trials on zilucoplan (RA101495)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings